Terminated PHASE4 INTERVENTIONAL 1-arm NCT02969876

Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine (VOR-IISR)

Sponsor: Massachusetts General Hospital

Conditions Depression Depression, Unipolar Depressive Disorder Major Depression

Updated 9 times since 2017 Last updated: Sep 23, 2019 Started: Aug 24, 2017 Primary completion: Aug 6, 2018 Completion: Aug 6, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Site was unable to reach Sponsor recruitment goals.

Other terminated trials from Massachusetts General Hospital

See all terminations from Massachusetts General Hospital

Other Depression trials with similar outcome

Browse all Depression trials

Listed as NCT02969876, this PHASE4 trial focuses on Depression and Depression, Unipolar and remains terminated or withdrawn. Sponsored by Massachusetts General Hospital, it has been updated 9 times since 2017, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE4

▶ Show 4 earlier versions

Nov 2019 — Jan 2021 [monthly]

Terminated PHASE4

Status: Recruiting → Terminated
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE4
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
Takeda

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States